D
에스엘에스바이오
246250KOSDAQ그외 기타 전문, 과학 및 기술 서비스업36.5 / 100
Reference Date: 2026-06-10
Financial Score4.0 / 40
News Sentiment12.5 / 25
Momentum10.0 / 20
Disclosure10.0 / 15
AI Analysis: the high debt ratio poses financial risk, ROE is below the industry average. Roughly flat over the past month, and news sentiment is neutral.
Company InformationBased on 2025 Annual Report
Business Overview
SLS Bio, established in 2007, specializes in pharmaceutical quality control, new drug development support, and in vitro diagnostic equipment. The company contributes to the pharmaceutical industry's advancement and public healthcare benefits through drug quality testing, generic drug promotion, and new drug development assistance.
Number of Employees
63people
Average Salary
35.7M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 48.804.0Point
PBR
3.96Industry Average 1.430.0Point
2.8x industry avg (risky)
ROE
-48.68Industry Average 0.940.0Point
Well below industry avg
Debt Ratio
26.32Industry Average 12.510.0Point
2.1x industry avg (risky)
Trend 2023~20250.0 / 10 points
Revenue Growth Rate
0.0 / 3
Avg ▼29.8% (2-year basis)
Operating Profit Growth Rate
0.0 / 3
Avg ▼799.7% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -10.6% (declining, 3yr)
Detailed News Sentiment
1 totalPositive 0Neutral 1Negative 0Average Sentiment Score 50
- Neutral달 향하는 아르테미스의 새 날개…‘40층 높이’ 3세대 스타십 날았다
우주발사체 스타십 발사 성공 소식은 관련 우주 기술 분야에 긍정적 영향을 미칠 수 있으나, 에스엘에스바이오의 직접적인 영향은 제한적입니다.
Detailed Momentum
52-week position4.0Point
52w mid range (50%)
Current 1,969Won52-week high 1,96952-week low 1,969
1-month return3.0Point
1m 0% (flat)
Volume trend3.0Point
Volume flat
Detailed Disclosure
2 totalPositive 0Neutral 2Negative 0
- Neutral[기재정정]분기보고서 (2026.03)2026-06-02
- Neutral분기보고서 (2026.03)2026-05-15